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Pro-opiomelanocortin (POMC)-deficiency causes severe obesity through hyperphagia 
of hypothalamic origin. However, low glucocorticoid levels caused by adrenal 
insufficiency mitigates against insulin resistance, hyperphagia and fat accretion in 
Pomc
-/- mice. Upon exogenous glucocorticoid replacement, (CORT) Pomc-/- mice 
show exaggerated responses including excessive fat accumulation, hyperleptinaemia 
and insulin resistance. To investigate the peripheral mechanisms underlying this 
glucocorticoid hypersensitivity we examined the expression levels of key 
determinants and targets of glucocorticoid action in adipose tissue and liver. Despite 
lower basal expression of 11-hydroxysteroid dehydrogenase type 1 (11-HSD1), 
which generates active glucocorticoids within cells, CORT-mediated induction of 
11-HSD1 mRNA levels was more pronounced in adipose tissues of Pomc-/- mice. 
Similarly, CORT treatment increased lipoprotein lipase mRNA levels in all fat depots 
in Pomc-/- mice, consistent with exaggerated fat accumulation. Glucocorticoid receptor 
(GR) mRNA levels were selectively elevated in liver and retroperitoneal fat of Pomc-/- 
mice but were corrected by CORT in the latter depot. In liver, CORT increased 
PEPCK mRNA levels specifically in Pomc-/- mice, consistent with their insulin 
resistant phenotype. Furthermore, CORT induced hypertension in Pomc-/- mice, 
independently of adipose or liver renin-angiotensin system (RAS) activation. These 
data suggest CORT-inducible 11-HSD1 expression in fat contributes to the adverse 
cardiometabolic effects of CORT in POMC deficiency, whereas higher GR levels 
may be more important in liver. 






Glucocorticoids exert pleiotropic effects on metabolism and energy partitioning. 
Centrally, they increase food intake and reduce energy expenditure whilst peripherally 
they promote insulin resistance, fat accumulation (Dallman et al. 1993; Kellendonk et 
al. 2002) and hypertension (Saruta 1996; Whitworth et al. 2001). Polymorphisms in 
the human glucocorticoid receptor NR3c1 gene (GR) are associated with 
glucocorticoid hypersensitivity, visceral obesity, hypertension and increased 
cardiovascular disease risk (Buemann et al. 1997; Rosmond et al. 2000; Ukkola et al. 
2001; Dodson et al. 2001; van Rossum et al. 2003). Many rodent models of obesity 
are characterised by hypercorticosteronemia, with weight gain normalised following 
adrenalectomy and reinstated by glucocorticoid replacement (Debons et al.1982; 
Freedman et al. 1986; Sainsbury et al.1997; Makimura et al. 2000). Although plasma 
glucocorticoid levels are normal in human idiopathic obesity (Flier 2004), it has been 
proposed that intra-adipose glucocorticoid action is selectively increased, through 
increased adipose expression of 11-hydroxysteroid dehydrogenase type 1 (11-
HSD1), the intracellular enzyme that regenerates active glucocorticoids from 
intrinsically inert 11keto-glucocorticoids (Andrew et al. 2002; Jamieson et al. 2000; 
Kotelevtsev et al. 1997).  
 
Obese humans (Rask et al. 2001; Paulmyer-Lacroix et al. 2002; Lindsay et al. 2003; 
Kannisto et al. 2004) and some rodent models of obesity (Masuzaki et al. 2001; 
Livingstone et al. 2000) have selectively increased adipose levels of 11-HSD1 and 
transgenic over-expression of 11-HSD1 in adipocytes causes hyperphagia, obesity, 
insulin resistance and hypertension despite unchanged systemic glucocorticoid levels 
(Kotelevtsev et al. 1997; Masuzaki et al. 2003). Hepatic over-expression of 11-





HSD1 has no effect on adiposity, but causes hypertension and insulin resistance 
(Paterson et al. 2004). Conversely, mice deficient in 11-HSD1 are insulin sensitised 
and resist the adverse metabolic effects of a high fat diet (Kotelevtsev et al. 1997; 
Morton et al. 2001; Morton et al. 2004).  
 
Proopiomelanocortin (POMC) is a polypeptide precursor which undergoes extensive 
postranslational modification to yield a range of smaller, biological active peptides. 
These include α-, β- and γ melanocyte stimulating hormone (MSH) and  
adrenocorticotropic hormone (ACTH), collectively known as the melanocortins. 
Inactivating mutations of the POMC gene in humans and mice results in a complex 
phenotype. Loss of melanocortin signalling within the hypothalamus cause 
hyperphagia and obesity (Krude et al. 1998; Yaswen et al.1999; Challis et al. 2004). 
Further, a failure to produce ACTH within the anterior pituitary causes adrenal 
insufficiency with low or absent circulating glucocorticoids (Krude et al. 1998; 
Yaswen et al.1999; Challis et al. 2004). Pomc-/- mice are therefore unusual amongst 
rodent models in that obesity develops in the absence of circulating glucocorticoids. 
However, glucocorticoid treatment exacerbates hyperphagia and obesity in adult 
Pomc
-/-
 mice and induces severe insulin resistance, hyperleptinemia and diabetes (Coll 
et al. 2005).  
 
We have tested the hypothesis that increased glucocorticoid action in peripheral 
tissues of glucocorticoid-treated Pomc-/- mice contributes to their apparent 
glucocorticoid-hypersensitivity and exaggerated metabolic syndrome-like phenotype. 
We further demonstrate that glucocorticoid replacement induces hypertension in 
Pomc
-/- mice, independently of RAS activation. 





MATERIALS AND METHODS 
Animals and corticosterone (CORT) replacement. The generation of Pomc-/- mice 
on a 129/SvEv background has been described previously (Challis et al. 2004). All 
mice were housed in standard conditions on a 12h light: 12h dark cycle (lights on 
7am) with ad libitum access to water and chow (4.5% fat diet, Special Diet Services, 
Witham, UK). Eight week-old male mice (n=5/group) were treated with 
corticosterone (25g/ml) in their drinking water, a dose that  results in similar plasma 
glucocorticoid levels and hypothalamic CRH mRNA levels in Pomc-/- and wild type 
mice (Coll et al. 2005). All animal protocols used in these studies were approved 
under the auspices of the UK Home Office Animals (Scientific Procedures) Act, 
1986.  
 
Blood Pressure Measurement. Systolic blood pressure was measured 
photoelectrically in the tail of restrained conscious mice using an IITC model 179 
analyser (Woodland Hills, California, USA). Prior to recording measurements, all 
mice underwent 3 periods of training to accustom them to the procedure. Mice were 
warmed at 32oC for 30 min before taking 10 consecutive readings. The first five were 
discounted and a mean value of systolic blood pressure was calculated from the last 
five readings. Five mice from each treatment group were measured. All analog 
recordings were analysed by an independent observer who was blinded to the 
genotype of the mice and any treatment they had received. 
 
Plasma hormone and lipid measurements. Animals were killed between 0800 and 
0900h by cervical dislocation. Trunk blood samples were collected into EDTA coated 
tubes (Sarstedt, Germany), centrifuged (6000g x 10min) and plasma stored at -80oC 





until required for assay. Non-esterified fatty acid (NEFA) and triglyceride levels were 
determined by commercial kits (NEFA, Roche Diagnostics, West Suffolk, UK; 
triglyceride, Dade Behring, Marburg, Germany). Plasma renin and angiotensinogen 
concentrations were determined as previously described (Morton et al. 2005). 
 
Tissue Morphology and hepatic triglyceride levels. Neutral lipids, cholesterol and 
fatty acids were identified by light microscopy at  x 40 magnification in cryostat liver 
sections (30m) stained with Oil red O (Sigma) and counter-stained with 
haematoxylin  as previously described (Morton et al. 2005). Hepatic triglycerides 
were extracted by homogenisation in isopropanol (10 volumes) then incubation  for 
45 min at 37oC and measured spectrophotometrically in supernatants (3000g x 10 
min) using reagent TR224221 (Alpha Laboratories).  
 
RNA extraction and northern blot analysis. Pieces of liver and adipose tissues 
(inguinal, retroperitoneal and epididymal) were rapidly frozen in dry ice, stored at -
80oC then homogenised in Trizol (Invitrogen, UK). Total RNA was purified using a 
binding matrix (RNaid Plus kit, BIO 101; Anachem, UK) and eluted in 
diethylpyrocarbonate-treated water containing 400 U/ml RNasin (Promega, 
Southampton, UK) and 10mmol/l dithiothreitol. RNA (5-10g) was blotted and 
hybridized to 32P-labelled cDNA probes for mouse 11-HSD1, GR, angiotensinogen, 
phosphoenolpyruvate carboxykinase (PEPCK), lipoprotein lipase (LPL) and 18S as 
previously described (Morton et al. 2005). Specific mRNAs were quantified using a 
phosphorimager (Fuji BAS FLA 2000) and Aida image analysis software (Raytek, 
Sheffield, UK) and are expressed in arbitrary units (A.U.) relative to 18S RNA. 
 





Statistical Analyses. The effects of genotype and corticosterone interactions were 
assessed by 2-way ANOVA followed by post-hoc Tukeys’ tests for group differences. 
Significance was set at p<0.05. Values are means ±SEM. 








 mice have reduced intra-adipose GC action  but exaggerated CORT 
mediated GC amplification.  
Corticosterone-treated Pomc-/- and wild type mice had similar plasma corticosterone 
levels and hypothalamic CRH mRNA levels (Coll et al. 2005). To examine potential 
mechanisms of CORT hypersensitivity in Pomc-/- mice, 11-HSD1 and GR mRNA 
levels were measured in epididymal, inguinal and retroperitoneal adipose depots. 
Adipose 11-HSD1 mRNA expression was lower in all untreated Pomc-/- compared to 
wild type mice (Fig. 1A) and was dramatically increased by CORT in both genotypes 
(Fig. 1A), with larger increases (2 to 4-fold greater) in Pomc-/- mice.  
 
Adipose expression of GR mRNA was higher in the retroperitoneal fat of Pomc-/- mice 
and restored to wild type levels by CORT treatment (Fig. 1B). GR mRNA levels did 
not differ in inguinal and epididymal fat between Pomc-/- and wild type mice, and 
were unaffected by CORT treatment in either genotype (Fig. 1B).  
 
To investigate mechanisms downstream of 11-HSD1/GR by which CORT-treatment 
selectively increases fat mass in Pomc-/- mice, adipose levels of mRNA encoding 
lipoprotein lipase (LPL), a glucocorticoid-regulated gene (Fried et al.1993), were 
measured. Although LPL mRNA levels were the same in untreated Pomc-/- and wild 
type mice in all depots, adipose LPL expression in Pomc-/- mice was markedly 
increased by CORT-treatment (Fig. 1C) consistent with increased  triglyceride uptake, 
and fat mass in Pomc-/- mice. In wild type mice, CORT-treatment increased LPL 
mRNA only in the inguinal depot, and to a lesser extent than in Pomc-/- mice (Fig. 





1C), suggesting adipose depot-dependent regulation of LPL by glucocorticoids in 
non-obese mice, consistent with previous data in rats (Freedman et al. 1986). 
 
Phosphoenolpyruvate carboxykinase (PEPCK) is an enzyme essential for 
gluconeogenesis in liver and for glycerol synthesis in adipose tissue (Pilkis & Granner 
1992; Reshef et al. 2003). PEPCK is a classical glucocorticoid target gene which is 
positively regulated by glucocorticoids in hepatocytes and negatively regulated in 
adipocytes (Sasaki et al.1984; Nechushtan et al. 1987). Consistent with this, adipose 
PEPCK mRNA levels were decreased in epididymal and retroperitoneal fat by CORT-
treatment in wild type mice (Fig. 1D). Surprisingly, given their glucocorticoid 
deficiency, Pomc-/- mice had lower levels of PEPCK mRNA in adipose tissue than 
wild type (Fig. 1D). However, although CORT treatment in Pomc-/- mice decreased 
PEPCK expression in inguinal and retroperitoneal adipose tissue (significantly lower 
than in CORT-treated wild type mice; p=0.01), it had no effect on PEPCK mRNA 
levels in epididymal adipose tissue, suggesting that other regulatory factors dominate 




 mice are dyslipidaemic, and have unaltered hepatic 11-HSD1 but higher 
GR mRNA levels. 
Hepatic 11-HSD1 mRNA levels were similar between the two genotypes (Fig. 2A) 
and unaffected by CORT (Fig. 2A). Hepatic GR mRNA levels were higher in Pomc-/- 
compared to wild type mice (Fig. 2B), but again CORT had no effect on GR mRNA 
levels (Fig. 2B).   





Hepatic PEPCK expression was lower in Pomc-/- than in wild type mice (Fig. 2C) and 
was increased by CORT treatment to levels equivalent to untreated wild type mice. In 
contrast, CORT decreased hepatic PEPCK mRNA levels in wild type mice (Fig.2C). 
 
Pomc
-/- mice showed markedly higher circulating triglyceride levels (Fig. 3A) and 
hepatic lipid accumulation than wild type mice (Fig. 3B), with 6-fold higher levels of 
hepatic triglyceride (P<0.001) (Fig. 3C). However, CORT had no effect on plasma 
triglyceride levels in either genotype (Fig. 3A), nor did it worsen the liver phenotype 
(Fig. 3C). Pomc-/- and wild type mice had similar plasma NEFA levels which were 
unaffected by CORT (Fig. 3D). 
 
CORT drives hypertension in Pomc
-/-




 mice had similar blood pressure to wild type mice (Fig. 4A). CORT markedly 
increased blood pressure only in Pomc-/- mice (Fig. 4A). Since hypertension following 
transgenic expression of 11-HSD1 in adipose or liver is associated with increased 
levels of angiotensinogen in each of these tissues, respectively (Masuzaki et al. 2001; 
Paterson et al. 2004) we hypothesised that a similar mechanism may drive CORT-
mediated hypertension in Pomc-/- mice. We therefore examined key components of the 
renin-angiotensin system (Guyton 1991). Pomc-/- mice had higher hepatic 
angiotensinogen mRNA levels than controls (Fig. 4B). However, CORT did not alter 
hepatic angiotensinogen mRNA levels in either genotype (Fig. 4B).  Consistent with 
lower intra-adipose GC action, adipose angiotensinogen mRNA levels were lower in 
Pomc
-/-
 mice in all adipose depots (Fig. 4C). CORT increased angiotensinogen mRNA 
levels specifically in epididymal adipose tissue of both genotypes (2 fold increase; 





P<0.001) (Fig. 4C) but had no effect on angiotensinogen mRNA levels in inguinal or 
retroperitoneal adipose tissue of either genotype (Fig. 4C). Plasma angiotensinogen 
concentrations did not differ with genotype or CORT (Fig. 4D). As has been found in 
another model of glucocorticoid deficient obesity (Morton et al. 2005), plasma renin 
concentration was markedly higher in Pomc-/- mice (Fig. 4E) but this was unaffected 
by CORT (Fig. 4E). 






Increased glucocorticoid action specifically in adipose (Masuzaki et al. 2001) or liver 
(Paterson et al. 2004) produce distinct metabolic syndromes with hypertension. 
Increased glucocorticoid receptor sensitivity is also associated with altered fat 
distribution, hypertension and cardiometabolic disease (Buemann et al. 1997; 
Rosmond et al. 2000; Ukkola et al. 2001; Dodson et al. 2001; van Rossum et al. 
2003). We hypothesised that altered tissue regeneration of active glucocorticoid 
and/or peripheral tissue sensitivity to GCs might explain in part the exaggerated fat 
accumulation, insulin resistance (Coll et al. 2005) and the hypertension observed in 
Pomc
-/- mice with glucocorticoid replacement.    
 
With fixed circulating glucocorticoid levels, 11-HSD1 and GR expression levels are 
the key determinants of GC action. Pomc-/- mice had lower adipose but similar hepatic 
levels of 11-HSD1 mRNA levels to wild type mice. CORT-treatment dramatically 
and more markedly increased 11-HSD1 in the adipose tissue of Pomc-/- mice. This 
was accompanied by a marked increase in the expression of the glucocorticoid 
inducible (Fried et al. 1993) gene LPL, which is consistent with the exaggerated 
accumulation of fat in these mice. Intriguingly, these data suggest that, at least in 
adipose tissue, 11-HSD1 itself is a glucocorticoid target gene. This finding is 
consistent with most (Jamieson et al. 1995; Voice et al. 1996; Hammami & Siteri 
1991; Bujalska et al. 1999), but not all (Napolitano et al. 1998) previous reports of 
glucocorticoid induction of 11-HSD1 in a variety of cell types. Although not 
specifically measured here, increased adipose 11-HSD1 activity is predicted to 
selectively amplify intra-adipose glucocorticoid concentrations, particularly when 
circulating levels of substrate are high. On the other hand, our data suggest that 





congenital glucocorticoid deficiency has little impact upon hepatic 11-HSD1 levels 
in vivo and is not regulated by corticosterone. In contrast, 11-HSD1 mRNA levels 
are highly and positively regulated by glucocorticoids in adipose tissue.  
 
GR levels are another major determinant of cellular glucocorticoid sensitivity 
(Vanderbilt et al. 1987; Geley et al. 1996). Small differences in GR mRNA levels can 
markedly alter glucocorticoid responsiveness (Geley et al. 1996; Reichardt et al. 
2000). Pomc-/- mice had elevated GR mRNA levels in liver and retroperitoneal 
adipose tissue, suggesting increased glucocorticoid sensitivity selectively in these 
depots. Following CORT replacement in Pomc-/- mice, GR mRNA levels were 
restored to wild type levels in retroperitoneal adipose tissue but not in liver, consistent 
with tissue- and time-specific differences in GR autoregulation (Reichardt et al. 2000; 
Sheppard et al. 1990; Holmes et al. 1990; Holmes et al. 1995; Holmes et al. 1997; 
Kalinyak et al. 1987; Dong et al. 1988).  
 
CORT had no additional effects on the hypertriglyceridaemia and fatty liver of the 
Pomc
-/- mice, and did not affect plasma NEFAs, which were normal in Pomc-/- mice. 
The CORT-driven caloric excess in Pomc-/- mice may drive a further increase in the 
flux of triglycerides from the liver, that, coupled with increased adipose uptake via 
LPL, maintains the circulating and liver triglyceride levels constant and is consistent 
with increased adipose tissue mass in CORT treated Pomc-/- mice (Coll et al. 2005). 
 
Adipose PEPCK is critical for glyceroneogenesis and is thus a key regulator of the 
level of fatty acid re-esterification (reviewed in (Reshef et al. 2003)). Unexpectedly, 
since glucocorticoids reduce adipose PEPCK, glucocorticoid deficient Pomc-/- mice 





had lower levels of PEPCK mRNA in all adipose depots. This was further decreased 
by CORT treatment. The lower level of PEPCK mRNA in untreated Pomc-/- mice may 
be due to their higher fed blood glucose levels (Nechushtan et al. 1987; Opherk et al. 
2004), thus reducing the need for glyceroneogenesis to generate glycerol-phosphate 
for fatty acid re-esterification. Pomc-/- mice have lower hepatic expression of PEPCK. 
This may not be due to lack of glucocorticoid signalling in liver, as mice with a liver-
specific knock-out of GR have normal levels of PEPCK in liver (Opherk et al. 2004), 
but may be related to the higher circulating levels of insulin in Pomc-/- mice compared 
to wild type (Coll et al. 2005). Insulin dominantly and negatively suppresses hepatic 
PEPCK in the fed state (Pilkis & Granner 1992). In CORT-treated wild type mice, the 
repressive effect of insulin predominated. Indeed, the decreased levels of PEPCK in 
these mice compared to untreated wild type mice may reflect the increase in insulin 
levels following CORT ( Coll et al. 2005). In contrast, hepatic PEPCK mRNA levels 
doubled following CORT treatment in Pomc-/- mice, consistent with hepatic insulin 
resistance and marked hyperinsulinaemia (Coll et al. 2005).  
 
Blood pressure in Pomc-/- mice is normal despite their hypoadrenal state. This implies 
that secondary mechanisms are invoked to maintain cardiovascular function when 
circulating aldosterone and corticosterone concentrations are chronically reduced 
(Coll et al. 2004). It seems likely that the increased renin activity which we have 
observed in Pomc-/- mice is part of this adaptive process. However, corticosterone 
replacement did not normalise renin activity and selectively increased blood pressure 
in Pomc-/- mice. This was not attributed to a further activation of the circulating renin-
angiotensin system, since neither renin nor its substrate angiotensinogen were 
increased. Indeed expression of angiotensinogen mRNA in liver and adipose tissues 





did not correlate with blood pressure. It seems likely that corticosterone augmented 
existing mechanisms that were already sustaining vascular function. Apart from renin, 
these secondary processes are likely to involve the hyperinsulinaemic (Sowers 2004) 
state of Pomc-/- mice (which is exacerbated by corticosterone treatment) (Coll et al. 
2005), the sympathetic nervous system (Rascher et al. 1979) (which is thought to 
explain glucocorticoid-induced hypertension in normal mice) or structural adaptation 
of the vasculature (Wallerath et al. 2004).  
 
In summary, we show that increased adipose tissue-specific sensitivity to 
glucocorticoids in Pomc-/- mice may result in part from exaggerated induction of 11-
HSD1 in adipose tissue with CORT administration. Whilst acknowledging that 
mRNA changes do not always translate to altered protein (or enzyme activity) levels, 
these data nevertheless suggest that 11-HSD1 might be a more potent mediator of 
intra-adipose GC action than the glucocorticoid receptor levels whereas in liver, 
higher GR levels contribute to the diabetogenic phenotype of the Pomc-/- mice.  
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FIG. 1. Mediators of GC action in adipose tissue of Pomc
-/-
 mice and effects of 
CORT-treatment on GC target genes 
(A) Representative northern blot showing levels of 11-HSD1 mRNA and 18S RNA 
in epididymal adipose tissue of Pomc-/- (-/-) and wild type (+/+) mice, either untreated 
or treated for 10 days with corticosterone (cort). (B-E) Quantitation of adipose tissue-
specific 11-HSD1 (B), GR (C), LPL (D) and PEPCK (E) mRNA levels in 
experimental mice. Epi, epididymal fat; ing, inguinal fat; retro, retroperitoneal fat. 
Data are presented as % of the value in untreated wild type mice (100%) and are the 
means ± SEM; n=5/group. Significance, *P<0.05, **P<0.01 and ***P<0.001. 
 
FIG. 2. Mediators of GC action in liver of Pomc
-/-
 mice and effects of CORT-
treatment on GC target genes  
Liver mRNA expression of (A) 11-HSD1 (B) GR and (C) PEPCK in Pomc-/- (-/-) 
and wild type (+/+) mice, either untreated or treated for 10 days with corticosterone 
(cort). Data are presented as % of the value in untreated control mice (100%) and are 
the means ±SEM; n=5/group. Significance, *P <0.05, **P<0.01 and ***P<0.001. 
 
FIG. 3. Dyslipideamia and fatty liver in Pomc
-/-
 mice. 
(A) Plasma triglyceride levels in Pomc-/- (-/-) and wild type (+/+) mice, either 
untreated or treated for 10 days with corticosterone (cort). (B) Oil Red O staining of 
neutral lipid in liver sections of wild type mice (+/+, left upper panel), CORT-treated 
wild type mice (+/+, left bottom panel), Pomc-/- (-/-, right upper panel) and CORT-
treated Pomc-/- (-/-, right bottom panel). Magnification is x40; red=Oil red O, blue = 
haematoxylin (nuclei). (C) hepatic triglyceride content in Pomc-/- (-/-) and wild type 





 (+/+) mice, either untreated or treated for 10 days with corticosterone (cort). (D) 
plasma levels of non esterified fatty acids (NEFA) in Pomc-/- (-/-) and wild type (+/+) 
mice, either untreated or treated for 10 days with corticosterone (cort). Data are means 
± SEM; (n=6/group). Significance, ***P<0.001. 
 
FIG 4. Corticosterone treatment increases blood pressure in Pomc
-/-
 mice: effect of 
CORT-treatment on the Renin-angiotensin system  
Effect of 10 days corticosterone treatment (cort) on (A) systolic blood pressure (B) 
renin concentration (C) plasma angiotensinogen (D) angiotensinogen (Agt) mRNA in 
adipose tissue (AT) and (E) angiotensinogen (Agt) mRNA levels in liver in wild type 
(+/+) and Pomc-/- (-/-) mice. Epi, epididymal fat; ing, inguinal fat; retro, 
retroperitoneal fat. Data are the means ± SEM, and for transcript levels are expressed 
relative to levels in untreated wild type mice (100%); n=5/group. Significance; 
*P<0.05, **P<0.01 and ***P<0.001. 
 




